Antiinfectives for Treatment of Acne

DrugDrug NameDrug Indication
DB13092MeclocyclineCurrently under investigation for the topical treatment of ulcerative oral mucositis [L797]
DB00634SulfacetamideFor the treatment of bacterial vaginitis, keratitis, acute conjunctivitis, and blepharitis.
DB01190ClindamycinFor the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci. May be useful in polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. May also be used to treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism. May be used vaginally to treat vaginosis caused by Gardnerella vaginosa. Clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, may be particularly useful for treating necrotizing fasciitis. May be used topically to treat acne.
DB12447NadifloxacinNot Available
DB00199Erythromycin Erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below [FDA label]: _Respiratory infections_ **Upper respiratory tract infections** of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) [FDA label]. **Lower-respiratory tract infections** of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes [FDA label]. **Pertussis (whooping cough)** caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals [FDA label]. **Respiratory tract infections** due to Mycoplasma pneumoniae [FDA label]. **Legionnaires’ Disease** caused by Legionella pneumophila. Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires’ Disease [FDA label]. **Diphtheria**: Infections due to Corynebacterium diphtheriae, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers [FDA label]. _Skin infections_ **Skin and skin structure infections** of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment) [FDA label]. **Erythrasma**: In the treatment of infections due to Corynebacterium minutissimum [FDA label]. _Gastrointestinal infections_ **Intestinal amebiasis** caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents [FDA label]. _Genital infections/STIs_ **Acute pelvic inflammatory disease** caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months [FDA label]. **Syphilis** caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy [FDA label]. **Chlamydia trachomatis**: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis [FDA label]. **Nongonnoconnal urethritis**: When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum [FDA label].
DB00446ChloramphenicolUsed in treatment of cholera, as it destroys the vibrios and decreases the diarrhea. It is effective against tetracycline-resistant vibrios. It is also used in eye drops or ointment to treat bacterial conjunctivitis.
DrugDrug NameTargetType
DB13092MeclocyclineOuter membrane protein Ftransporter
DB13092MeclocyclineOuter membrane porin Ctransporter
DB13092Meclocycline30S ribosomal protein S7target
DB13092MeclocyclineTetX family tetracycline inactivation enzymeenzyme
DB00634SulfacetamideDihydropteroate synthasetarget
DB00634SulfacetamideDihydropteroate synthase type-1target
DB00634SulfacetamideFolic acid synthesis protein FOL1target
DB01190Clindamycin50S ribosomal protein L10target
DB01190ClindamycinCytochrome P450 3A4enzyme
DB01190Clindamycin23S rRNAtarget
DB00199Erythromycin23S rRNAtarget
DB00199ErythromycinCytochrome P450 3A4enzyme
DB00199ErythromycinCytochrome P450 3A7enzyme
DB00199ErythromycinMultidrug resistance protein 1transporter
DB00199ErythromycinSolute carrier organic anion transporter family member 1B1transporter
DB00199ErythromycinMotilin receptortarget
DB00199ErythromycinPotassium voltage-gated channel subfamily H member 2target
DB00199ErythromycinCytochrome P450 3A5enzyme
DB00199ErythromycinSolute carrier organic anion transporter family member 1B3transporter
DB00199ErythromycinBile salt export pumptransporter
DB00199ErythromycinBacterial 50S Ribosomal Subunittarget
DB00199ErythromycinCanalicular multispecific organic anion transporter 1transporter
DB00199ErythromycinSolute carrier organic anion transporter family member 1A2transporter
DB00446ChloramphenicolComplement decay-accelerating factortarget
DB00446ChloramphenicolDr hemagglutinin structural subunittarget
DB00446ChloramphenicolCytochrome P450 2C19enzyme
DB00446ChloramphenicolCytochrome P450 3A4enzyme
DB00446ChloramphenicolCytochrome P450 3A5enzyme
DB00446ChloramphenicolCytochrome P450 3A7enzyme
DB00446ChloramphenicolSolute carrier family 22 member 6transporter
DB00446Chloramphenicol50S ribosomal protein L16target
DB00446ChloramphenicolChloramphenicol acetyltransferase 3enzyme
DB00446ChloramphenicolChloramphenicol acetyltransferaseenzyme
DB00446ChloramphenicolChloramphenicol 3-O phosphotransferaseenzyme
DB00446ChloramphenicolCytochrome P450 2C8enzyme